Upgrade to SI Premium - Free Trial

Bernstein SocGen on Bristol-Myers Squibb Co. (BMY): 'Hengrui deal highlights acceleration possibilities in China'

May 13, 2026 8:04 AM
Bernstein SocGen Group analyst Courtney Breen reiterated a Market Perform rating and $58.00 price target on Bristol-Myers Squibb Co. (NYSE ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments